Troubled Drugmakers Mallinckrodt, Endo Officially Announce $6.7B Merger
As per the Thursday release, Endo will be folded into Mallinckrodt, which will then continue as the holding entity for the combined companies. Post-merger, the company will be listed on the New York Stock Exchange and is projected to generate around $3.6 billion in revenue this year.
(Reuters) -All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals, whose medicines are part of the second ...
(Reuters) - Mallinckrodt and Endo, drugmakers with a shared history of facing U.S. opioid litigation, have agreed to merge in a deal valued at nearly $7 billion. Under the terms of the agreement ...
Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...
An opaque system of rebates and discounts makes understanding a drug’s true price near impossible, even for experts. Can ...
Endo and Mallinckrodt, two drugmakers seeking to recover from opioid lawsuits and bankruptcies, are betting a combination will help. Investors took a dim v ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback